Jaime Kratz, MD
Allergy & Immunology · Port Richey, FLNPI 1851391411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,366 of the $134,889 with a category attached, or 81.1%. 36 manufacturers reported payments, led by AstraZeneca at 42.1% of the total. Reporting peaked in 2024 at $43,153 and has fallen 65.4% since, to $14,927 in 2025. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 949 payments — averaging $142.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- GSK$33K
- Sanofi$24K
- Amgen$13K
- Regeneron Healthcare Solutions, Inc.$2K
- CSL Behring$772
- plus $6K from 30 others
Across 195 payments — averaging $478.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$37K
- Regeneron$32K
- GSK$18K
- AstraZeneca$5K
What the payments were for
- Consulting fees$2,2282%
- Speaking & faculty fees$109,36681%
- Travel & lodging$3,6873%
- Food & beverage$19,26114%
- Education$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 206 | $56,744 |
| GSK | 162 | $32,867 |
| Sanofi | 90 | $23,571 |
| Amgen(2 entities) | 71 | $12,518 |
| Regeneron Healthcare Solutions, Inc. | 116 | $2,450 |
| CSL Behring | 44 | $772 |
| Novartis | 34 | $731 |
| Octapharma USA, Inc. | 14 | $722 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $704 |
| Genentech USA, Inc. | 30 | $696 |
| Pfizer | 23 | $421 |
| LEO Pharma Inc. | 14 | $312 |
| AbbVie | 13 | $233 |
| Grifols USA, LLC | 9 | $218 |
| Pharming Healthcare, Inc. | 10 | $196 |
| Sanofi-aventis U.S. LLC | 2 | $191 |
| Boehringer Ingelheim | 10 | $187 |
| Galderma Laboratories, L.p. | 10 | $172 |
| Biocryst US Sales Co., LLC | 6 | $147 |
| Optinose US, Inc. | 8 | $138 |
| Shire North American Group Inc | 6 | $136 |
| Kaleo, Inc. | 8 | $130 |
| Teva Pharmaceuticals USA, Inc. | 8 | $113 |
| Phadia US Inc. | 6 | $105 |
| Aimmune Therapeutics, Inc. | 4 | $98 |
| ADMA Biomanufacturing LLC | 5 | $72 |
| Lilly USA, LLC | 2 | $46 |
| Blueprint Medicines Corporation | 2 | $38 |
| Incyte Corporation | 2 | $36 |
| Circassia Inc. | 2 | $29 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Covis Pharma GmbH | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Alk-abello, Inc | 1 | $12 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,889 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 124 | $484,477 |
| Dupixent PenDupilumab | 43 | $177,653 |
| TezspireTezepelumab-Ekko | 38 | $159,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $142,609 |
| XolairOmalizumab | 49 | $133,656 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $64,879 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $53,953 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $44,972 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $33,485 |
| Spiriva RespimatTiotropium Bromide | 34 | $30,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $24,061 |
| XhanceFluticasone Propionate | 17 | $17,090 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $14,877 |
| Azelastine Hcl | 230 | $6,583 |
| BreynaBudesonide/Formoterol Fumarate | 38 | $6,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $56,744 | $198,058100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $32,867 | $178,664236 claims |
| CSL BehringPrivigen, Hizentra | $772 | $118,83324 claims |
| Grifols USA, LLCGamunex-C | $218 | $44,97213 claims |
| Boehringer IngelheimSpiriva Respimat | $187 | $30,33534 claims |
| Optinose US, Inc.Xhance | $138 | $17,09017 claims |
| Hikma Pharmaceuticals USAEpinephrine | $21 | $3,65823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Port Richey
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.